The Trump administration is considering Sara Brenner, a senior adviser at the Department of Health and Human Services, and Jeff Vacirca, head of a New York oncology group, for leadership positions at the FDA bloomberg.com/news/articles/…
Mostly Biotech 🧬 retweeted
2 reliable #biotech quant indicators approaching thresholds from which reversals have occurred.
1- % of Bios within 5% of 52 week lows at 34% is 3rd highest in 3 years, fast approaching the 40% of Oct 2023 important trading low.
2- % of Bios above their 50-DMA at 21% is where short-term reversals occur and closing in on where high probability intermediate upside begins. The elastic band is getting reliably stretched in this baby-out-with-the-bathwater-correlation-approaching-one phase.
Mostly Biotech 🧬 retweeted
$KURA Highlights from this Week's Conferences:
More than a menin inhibitor:
“We are a menin inhibitor and a degrader.”
Dosing:
“We are once a day dosing, very long half-life.” “The others have twice a day dosing -much shorter half-lives.”
Impact of a longer half-life:
“I think that pulsatile hitting of the target is what results in the cytopenias and potentially in these adaptations of MEN-1 resistance.”
“I think men-1 resistance is a big issue in monotherapy. What we have shown is that it is not an issue for Ziftomenib.” “We have among the lowest levels of MEN-1 resistance mutations. I believe that there is another paper coming at ASH that will also show that.” “Where you look at Revumenib that has about a 41% men-1 mutation developing.”
(A MEN1 mutation is a change in the MEN1 gene that alters the menin protein and causes acquired resistance to the treatment.)
“What that tells me is that there is no way that I would use one that causes a huge amount of MEN-1 mutations up front, because you ruin the whole class.”
Relative to the J&J Drug:
“So they have removed the patients that probably dropped out in the first cycle due to toxicity or rapid progression. That is not the same thing as what any of the other competitors are presenting. . . .So really what you saw is their best foot forward, but it will come down significantly. . . . I see the response rate probably being 20 to 30% range, just like all the other menin inhibitors.”
“The menin inhibitor story is now in the combination setting - in earlier lines. And we have seen some of their data in the combination early line setting and it certainly does not look superior to ours. Ours actually regularly and consistently looks superior. Not only in efficacy but absolutely from a safety perspective. So I think you are going to see us continue to win- not only in the combinations, but in the frontline due to superior safety and I think superior efficacy as well.”
Mostly Biotech 🧬 retweeted
TAIWAN 🇹🇼 BANS SHORT SELLING BELOW THE PREVIOUS CLOSE ON ALL STOCKS STARTING MONDAY, THE FIRST BLANKET CURB SINCE 2015
Mostly Biotech 🧬 retweeted
FDA statement on $CAPR is nearly unprecedented. We must send the message via the @USDOJ, which I am absolutely loathe to recommend on anyone for obvious reasons, that manipulating clinical trial data is the worst possible crime in biotech and life sciences.
cc @linda_marban @AGToddBlanche
Mostly Biotech 🧬 retweeted
FDA statement on $CAPR is nearly unprecedented. We must send the message via the @USDOJ, which I am absolutely loathe to recommend on anyone for obvious reasons, that manipulating clinical trial data is the worst possible crime in biotech and life sciences.
cc @linda_marban @AGToddBlanche
$IOVA quietly dropped an interesting commercial update at today’s Jefferies conference.
Management confirmed price increases effective January 1, 2027:
• Amtagvi: +9%
• Proleukin: +7%
With Amtagvi sales already growing and operating losses shrinking, higher pricing could provide another revenue and margin tailwind in 2027.
Actual net revenue gains will depend on reimbursement and discounts, but this is another lever for improving profitability.
Source: ir.iovance.com/events/event-…
#VIX hit ~40 (39,53 to be exact) on Friday! 👀
This normally marks the bottom! 🚨
1
157
Mostly Biotech 🧬 retweeted
UnitedHealth is suing the U.S. 🇺🇸 government over its lowered 2027 Medicare Advantage star ratings, which could cost the insurer billions in bonus payments.
The company claims CMS improperly calculated ratings for 45 contracts, which it says should be 0.5 to 1.5 stars higher.
No need to panic, if your not Leveraged, 3x ETF-ed, Option-ed, and Margin-ed!
Stay calm, & add if you have 💰
You will be fine in 2027!
95

























